Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Articles|December 9, 2010
Quiz on Dementia, Anxiety, Bipolar Disorder
Key Takeaways
- ” bullets, each ≤30 words, complete sentences, varied openers, and each ending with a period.
Do patients with the personality trait alexithymia have trouble understanding the written language? What percentage of patients with dementia have at least one psychiatric comorbidity? These and more in this quiz.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
3
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5